Korean J Lab Med.  2011 Apr;31(2):98-100. 10.3343/kjlm.2011.31.2.98.

Overlapping Presence of Macroamylasemia and Hyperamylasemia in Acute Pancreatitis

• Cho SY
• Lee A
• Lee HJ
• Suh JT

• KMID: 1094348
• DOI: http://doi.org/10.3343/kjlm.2011.31.2.98

Abstract

No abstract available.

MeSH Terms

Acute Disease
Amylases/blood
Humans
Hyperamylasemia/complications/*diagnosis
Isoenzymes/analysis
Liver Cirrhosis/complications/diagnosis
Male
Middle Aged
Pancreatitis/complications/*diagnosis/radiography
Tomography, X-Ray Computed

Figure

• 

  Fig. 1 Findings of abdominal computed tomography performed when the patient showed acute pancreatitis. A cystic lesion (arrows, 1.5 cm) in the pancreatic head region (A) and mild swelling of the pancreas (B) are observed.

• 

  Fig. 2 Trends in the serum amylase and lipase levels from the time of diagnosis of acute pancreatitis (*) to the time of diagnosis of macroamylasemia (**). Serum amylase levels are high for about 4 months, while lipase levels fall near the upper reference limit. Macroamylasemia may occur when lipase level returned to normal, unlike the amylase level, which was sustained at a high level.

• 

  Fig. 3 Serum amylase isoenzyme electrophoresis (A) and capillary electrophoresis (B and C). (A) The P-type amylase level increased to 1,664.13 IU/L (75.30% of the total amylase concentration). The S-type amylase level is within the reference interval (545.87 IU/L; 24.70%). Serum protein capillary electrophoresis (B) and immunotyping (C) show polyclonal gammopathy with a beta-gamma bridge pattern, which is a typical pattern in patients with liver cirrhosis. In immunoglobulin quantification, the estimated IgG and IgA levels were 3,850 mg/dL (reference interval, 700-1,600 mg/dL) and 664 mg/dL (reference interval, 70-400 mg/dL), respectively.

Reference

1. Choi S, Ihm C, Jang S. Evaluation of the clinical usefulness for pancreatic amylase in acute pancreatitis. Korean J Lab Med. 2003; 23:98–103.

2. Klonoff DC. Macroamylasemia and other immunoglobulin-complexed enzyme disorders. West J Med. 1980; 133:392–407. PMID: 6162278.

3. Sagristani M, Guariglia R, Pocali B, De Rienzo M, Guastafierro S, Romano G, et al. Macroamylasemia in a patient with multiple myeloma. Leuk Lymphoma. 2002; 43:1705–1707. PMID: 12400618.

4. Lankisch PG, Doobe C, Finger T, Lübbers H, Mahlke R, Brinkmann G, et al. Hyperamylasaemia and/or hyperlipasaemia: incidence and underlying causes in hospitalized patients with non-pancreatic diseases. Scand J Gastroenterol. 2009; 44:237–241. PMID: 18819039.

5. Barera G, Bazzigaluppi E, Viscardi M, Renzetti F, Bianchi C, Chiumello G, et al. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics. 2001; 107:E93. PMID: 11389291.

6. Van Gossum A. Macroamylasemia: a biochemical or clinical problem? Dig Dis. 1989; 7:19–27. PMID: 2466587.

7. Yoshida K, Minegishi Y, Okawa H, Yata J, Tokoi S, Kitagawa T, et al. Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol. 1997; 14:85–89. PMID: 9021818.

8. Galasso PJ, Litin SC, O'Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc. 1993; 68:349–354. PMID: 7681133.

9. Kobayashi T, Nakayama T, Kitamura M. Electrophoretic identification of serum immunoglobulins linked to amylase:macroamylase. Clin Chim Acta. 1978; 86:261–265. PMID: 668118.

10. McPherson RA, Pincus MR, editors. Henry's clinical diagnosis and management by laboratory methods. 2007. 21st ed. St. Louis: Elsevier Saunders;p. 231–244.